PARP1 and brain ischemia: Third, based on previous studies regarding the roles of NAD+ and PARP-1 in such diseases as brain ischemia, it is warranted to initiate preclinical trials to determine the effectiveness of NAD+ and PARP inhibitors for treating such diseases as brain ischemia.